article thumbnail

Roche buys into Alnylam heart drug in cardiovascular research bet

BioPharma Drive: Drug Pricing

The Swiss pharma company is the latest large drugmaker to invest big in an experimental heart treatment, after years of prioritizing medicines for cancer and immune diseases.

article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Their work focuses on creating ‘digital twin generators’ – AI-driven models that predict how a patients disease may progress over time. These digital twins allow pharmaceutical companies to design clinical trials with fewer participants, while still providing reliable evidence to assess a drugs effectiveness.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Women in STEM with Kristina Torfgard

Drug Target Review

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company. I experienced challenges in cultural differences working with US, UK, Japan, and China.

article thumbnail

Zebrafish for Disease Modeling and Drug Screening in Pediatric Cancers

biobide

Pediatric cancers exhibit differences at the genetic level compared to the same form of adult disease, which may influence the selected treatment. This New Alternative Model (NAM) provides a platform for High-Content Screening through disease modeling through the transplantation of primary patient tumors into immunocompromised lines.

Disease 59
article thumbnail

Level Up Your Lab Data: New Use Cases for Improving Time to Treatment

Fierce BioTech

Listing Image QuartzListingLogo_250x190_norstella.png Listing Introduction Real-world data is essential to gaining insights into a patient’s diagnostic journey, but many pharma companies may not be using lab data, in particular, to its full potential. On Demand Start Date Tue, 10/29/2024 - 12:00

article thumbnail

Equitable Clinical Trial Access for Women & Minorities

Fierce BioTech

Discover how a top 10 pharma company is making strides in addressing this disparity by harnessing the power of H1's diversity insights to build an equitable clinical trial for cardiovascular disease. H1 Resource Type Research clinical trial access 250x190E (1).png

article thumbnail

How combining datasets from multiple sources can inform and improve commercial strategies

Fierce BioTech

How combining datasets from multiple sources can inform and improve commercial strategies Hundreds of rare disease treatments have entered the market over the past decade—thanks largely to a combination of government incentives, strong urging from patient advocacy groups and advances in cell and gene therapies.